Suicide gene therapy of malignant melanoma essentially requires efficient gene transfer and highly selective therapeutic gene expression. To achieve this, recombinant adeno-associated virus (rAAV) particles were constructed containing the tissue-specific promoter of the human melanoma inhibitory activity (hMIA) gene combined with four copies of the enhancer element of the murine tyrosinase gene. Three melanoma and one cervix carcinoma cell line were infected with rAAV particles carrying a reporter gene under control of the enhancer/hMIA promoter in order to determine transcriptional activity and specificity of this system. Viral particles containing the enhancer/hMIA promoter mediated reporter gene activity only in melanoma cells, whereas infection with a cytomegalovirus (CMV)-based promoter construct induced unspecific gene expression. Correspondingly, transient transduction with viral particles bearing the HSVtk gene under the control of the enhancer/MIA promoter elements followed by treatment with ganciclovir (GCV) resulted in growth inhibition only in melanoma cells, whereas the CMV promoter-based construct induced unspecific cytotoxicity. In vivo experiments in nude mice demonstrated that tumors originating from human melanoma cells disappeared after stable, but not transient transduction with vectors bearing the HSVtk gene under the control of the enhancer/hMIA promoter in response to GCV application. In face of higher transduction efficiency, these rAAV particles might therefore be a useful tool for suicide gene therapy of malignant melanoma.
M alignant melanoma is a significant and growing health problem with an incidence rate increasing faster than that of any other malignancy. [1] [2] [3] Approximately 53,600 cases and 7400 deaths attributable to melanoma are predicted to occur in 2002 in the USA. 4 Its highly metastatic nature and resistance to most chemotherapeutic agents leading to poor efficacy of currently available treatments indicate the need for novel therapeutic strategies, such as induction of tumor cell death by suicide gene therapy. 5 Cell death can be mediated by prodrug-activating enzymes, like the herpes simplex virus thymidine kinase (HSVtk). HSVtk phosphorylates the substrate ganciclovir (GCV) to GCV monophosphate, which is then converted by cytoplasmic enzymes to the triphosphate metabolite. GCV triphosphate, when incorporated into replicating DNA, interferes with DNA chain elongation and results in cell death. 6, 7 In addition, GCV treatment also exerts a bystander effect as it causes not only death of HSVtkexpressing cells but also of neighboring non-HSVtkcontaining cells. 8 Delivery of HSVtk encoding DNA into the tumor cells requires efficient vector systems like recombinant viruses. The human parvovirus adenoassociated virus (AAV) is currently considered one of the most promising viral vector systems, because of a unique combination of attractive properties. Requiring coinfection by a helper virus for productive infection, AAV is regarded as being naturally defective in replication. 9 In addition, AAV is not known to cause any human disease. Another feature of AAV derived vectors is their capacity to infect both mitotic and postmitotic cells of varying cell types. Also, AAV vectors have the property to mediate long-term gene expression of foreign genes, based on transduction of the recombinant genomes into stable episomal forms and/or integration into the host genome. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Beside efficient delivery, suicide gene therapy most essentially requires highly selective expression of the therapeutic gene. To ensure selective cell killing after nonspecific infection, expression of the suicide gene has to be regulated by tissue-specific DNA control elements. In case of malignant melanoma, promoters and enhancers of genes involved in melanin biosynthesis, for example, of the tyrosinase gene, have been used in different studies to restrict gene expression to tumor cells and melanocytes. [20] [21] [22] [23] [24] [25] Evidence obtained from in vitro and in vivo experiments indicated that in addition, expression of the melanoma inhibitory activity (MIA) protein is highly restricted to melanoma. MIA plays an important role in melanoma metastasis and invasion. 26, 27 and has been identified as a highly specific and sensitive marker for malignant melanoma. [28] [29] [30] It has been shown that a fragment of approximately 1.4 kb 5 0 flanking DNA of the human gene conferred selective gene expression to melanoma cells, but not to melanocytes. 31 MIA activity is also detectable in chondrosarcomas, adenocarcinomas and chondrocytes. 28, 31, 32 In this study, gene regulatory elements from the tyrosinase and the MIA gene were combined to highly restrict HSVtk expression to melanoma cells and packed into recombinant AAV (rAAV) particles for efficient gene transfer. The results obtained demonstrated that infection with AAV mediated strong and highly selective suicide gene expression in vitro, and also the results in vivo may be an indicator for a stable transcriptional activity making them to a promising tool for tumor suicide gene therapy.
Materials and methods

Cloning and construction of rAAV particles
For all constructs, pTRUF2 was used as viral vector backbone. 33 Two different length variants of the human MIA promoter (kindly provided by AK Bosserhoff, Regensburg, Germany), consisting of 1386 bp (hMIA) and 493 bp (hMIA(493)), respectively, as tissue-specific DNA control elements for HSVtk suicide gene therapy of malignant melanoma were used. 30 Since both MIA promoter fragments exhibited specific but only weak transcriptional activity (data not shown), we combined hMIA and hMIA(493) with four copies of a DNA enhancer element of the murine tyrosinase gene, which have previously been shown to enhance melanoma-specific gene expression, 34 resulting in the constructs hMIAIV and hMIA(493)IV.
For generating the hMIAIV fragment, the murine enhancer element was amplified by polymerase chain reaction (PCR) using the primers AP-Tyr1 (5 0 -ACCTAAGCTTGTCGA CAGTTCCTGCCAGCTGACTTTGTCAAGACAG-3 0 ), AP-Tyr2 (5 0 -GTTACTCGAGTGTGCCAGGACCCCA GCAGAGACTTTGTCAAGACAG-3 0 ) and the template plasmid phsTyr(0,2)-CAT. 35 AP-Tyr1 introduced a HindIII and a SalI site, whereas the 3 0 primer AP-Tyr2 introduced a XhoI site into the PCR product. The HindIII-XhoI restricted enhancer PCR fragment was inserted into the HindIII-SalI linearized plasmid phMIA-CAT (obtained by AK Bosserhoff) . By following this strategy, four enhancer elements were fused into the plasmid resulting in phMIAIV-CAT. Finally, the hMIAIV fragement was recovered by HindIII-BamHI restriction and inserted into the HindIIIBamHI linearized plasmid pSK resulting in pSKhMIAIV.
The therapeutic constructs pTRUF2/hMIAIV-HSVtk and pTRUF2/hMIA(493)IV-HSVtk combined the enhancer/hMIA promoter fusions with the HSVtk gene. For generating pTRUF2/hMIAIV-HSVtk, the hMIAIV fragment was taken out of phMIAIV-CAT by ClaI and NotI restriction, both sites were blunted, and the fragment was inserted instead of the p800 promoter into the blunted EcoRI site of pTRUF2/p800-HSVtk (kindly provided by S Sieger, German Cancer Research Center, Heidelberg, Germany). This contains the HSV1 thymidine kinase sequence originally found in pGT60hAngio (InvivoGen, San Diego, CA). For generating pTRUF2/hMIA(493)IVHSVtk, the MIA promoter was removed from the previous construct by XbaI restriction, and hMIA(493) was recovered from phMIA(493)-CAT (obtained by AK Bosserhoff) after digestion with HindIII-BamHI. All sites were blunted while the two fragments were fused.
In the reporter gene construct pTRUF2/hMIAIV-EGFP the gene of the enhanced green fluorescent protein (EGFP) was cloned downstream of the enhancer/hMIA promoter. Therefore, in a first step, the EGFP-1 sequence was taken out of pEGFP-1 (Clontech, Palo Alto, CA) by NotI-XhoI restriction, and inserted into the SalI-XhoI linearized plasmid pTRUF2 resulting in pTRUF2/CMV-EGFP. For this strategy, the NotI and SalI restriction site, respectively, were blunted. Finally, hMIAIV was recovered from pSKhMIAIV after digestion with HincII-BamHI and inserted instead of the CMV promoter in the EcoRI blunt-BamHI opened plasmid pTRUF2/CMV-HSVtk.
For the establishment of a stable melanoma cell line the construct pTRUF2/hMIA(493)IV-HSVtk-IRES2-EGFP was cloned in a two-step procedure. Firstly, the HSVtk gene was recovered from pGT60hAngio after digestion with XhoI-EcoRI and inserted in the XhoI-EcoRI linearized plasmid pIRES2-EGFP (Clontech, Palo Alto, CA) resulting in pHSVtk-IRES2-EGFP. Secondly, the HSVtk-IRES2-EGFP sequence was taken out of pHSVtk-IRES2-EGFP by BglII-NotI restriction, meanwhile the HSVtk gene was removed from pTRUF2/hMIAIV-HSVtk by NotI-SacI restriction. For fusion of the fragments, all restriction sites were blunted. The EGFP gene in the resulting construct was applied as a selection marker.
In addition, cytomegalovirus (CMV) promoter-based constructs (pTRUF2/CMV-EGFP, pTRUF2/CMV-HSVtk) were generated serving as controls with high and unspecific transcriptional activity. While the construction of pTRUF2/ CMV-EGFP was still described above, pTRUF2/CMVHSVtk was generated by cloning the CMV promoter EcoRI blunt-XbaI fragment from pTRUF2 in the HindIII blunt-XbaI linearized plasmid pTRUF2/hMIAIV-HSVtk replacing the hMIAIV promoter.
For efficient DNA delivery, rAAV were constructed using the generated pTRUF2 constructs (Fig 1) . 36 Titrations of
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Cell culture
All cells were cultivated at 371C, in an atmosphere of 95% air and 5% CO 2 . The appropriate medium was supplemented with 100,000 IU/l penicillin, 100 mg/l streptomycin and 10% fetal calf serum. Human (MeWo and SK-Mel-23) and murine (B16) melanoma cells were maintained in RPMI-1640 medium with glutamax-I (Gibco BRL, Eggenstein, Germany), human cervix carcinoma cells (HeLa) and the 293T cells were maintained in DMEM medium with glutamax-I (Gibco BRL, Eggenstein, Germany).
Flow cytometry and cell sorting
Viral infection efficiency was determined by FACS analysis as follows: 2 days after seeding of 5 Â 10 4 cells in six-well plates the cells were infected with rAAV at a multiplicity of infection (MOI) of 20 infectious particles overnight in OPTI-MEM I medium with glutamax-I (Gibco BRL, Eggenstein, Germany). Thereafter, the medium was replaced by the standard cell culture medium. After 2 days, the cells were trypsinized, washed twice with cold PBS and resuspended in cold PBS supplemented with 1% BSA and 200 mM EDTA. Flow cytometry was performed with a FACSCalibur System (BD Biosciences, Belgium) equipped with a 488 nm argon laser. Gating was carried out to exclude cell debris as well as dead cells. Data from 10,000 cells/sample were collected and results were shown in both dot plot and histogram plot. Using the parameter forward scatter (FSC) and side scatter (SSC) in a dot plot, it was possible to estimate cell size and granularity, which helped to distinguish living cells from damaged or dead cells, since 
Thymidine uptake
At 2 days after seeding of 5 Â 10 4 cells, the cells were infected as described. After two days 12.5 mM GCV was added to the cells. After 2 hours, 185 kBq (methyl-3 H)-thymidine (Amersham, Braunschweig, Germany; specific activity 185 GBq/mmol; radioactive concentration 37 MBq/ml; radiochemical purity 99.2%) per well was added for 4 hours. After removal of the medium, the cells were washed twice with ice-cold PBS. The lysis was carried out with 0.6 M perchloric acid and a cell scraper. After 30 minutes on ice, the lysates were vortexed and rotated at 1500 g for 5 minutes. The supernatant was removed, the pellets were washed with 0.6 M perchloric acid, rotated again for 5 minutes and resuspended in 0.3 M NaOH at 371C. Radioactivity in the pellets (acidinsoluble fraction of 3 H-thymidine incorporated into DNA) was counted using Pico-Fluor-15 (Canberra Packard, Schwadorf, Austria) and an LSC TRICARB 2500TR (Canberra Packard) scintillation counter. The measured radioactivity was standardized to the viable cell number as determined by a Coulter counter (Beckman Coulter, Unterschleissheim, Germany).
GCV uptake
At 2 days after seeding of 5 Â 10 4 cells in six-well plates, the cells were infected as described. After 2 days, 185 kBq H)-GCV (Moravek Biochemicals, Brea, USA; specific activity 351 GBq/mmol, radioactive concentration 37 MBq/ml, radiochemical purity 98.5%) was added per well. After 4 hours, cells were washed twice with ice-cold PBS and lysed with ice-cold 0.3 M NaOH and a cell scraper. The lysate was counted using Pico-Fluor-15 and Tissue-specific gene therapy of malignant melanoma F Schoensiegel et al an LSC TRICARB 2500TR scintillation counter. The measured radioactivity was standardized as described.
Growth inhibition after GCV treatment
At 2 days after seeding 5 Â 10 3 cells in 24-well plates, cells were infected as described. At 2 days after infection, the medium was replaced by cell culture medium containing 12.5 mM GCV. The viable cell number was determined after 2 days of GCV exposure using a Coulter counter.
In vivo evaluation of tumor growth
The influence of transient viral transduction on tumor growth was determined as follows: 14 female Swiss CD1 nu/nu mice (IFFA CREDO, France) were divided into two groups: group 1, inoculated with noninfected 2.0 Â 10 6 MeWo cells; group 2, inoculated with 2.0 Â 10 6
MeWo cells infected overnight with rAAV/hMIAIVHSVtk. In a succeeding experiment, nine mice were divided into three groups: group 1, inoculated with noninfected 1.2 Â 10 6 HeLa cells; group 2, inoculated with 1.2 Â 10 6 HeLa cells infected overnight with rAAV/ CMV-HSVtk; group 3, inoculated with 1.2 Â 10 6 HeLa cells infected overnight with rAAV/hMIAIV-HSVtk.
For challenge with a stable HSVtk-expressing cell line, 10 mice were divided into two groups: group 1, inoculated with 2.0 Â 10 6 MeWo wild-type cells, and group 2, inoculated with 2.5 Â 10 6 MeWo cells stable infected with hMIA(493)IV-HSVtk-IRES2-EGFP (MeWo K4 cells). The cells were suspended in 100 ml OPTI-MEM I medium and injected s.c. in the right flank of the mice. GCV (Hoffmann-La Roche AG, Basel, Switzerland) treatment was started after the tumors reached 5 mm in diameter (2-3 weeks after transplantation). GCV (80 mg/kg) in 200 ml 0.9 % NaCl solution was injected i.p. once (transiently transduced cell lines) or twice (stable HSVtk-expressing cell line) daily. The tumor size was monitored by measuring every day two diameters at right angle with a calliper. The volume was calculated using the formula 4/ 3pr 3 (r ¼ sum of the two diameters divided by 4).
Synthesis of 5-[ 131 I]iodo-deoxycytidine
The synthesis was performed by the Tl(TFA) 3 /[ 131 I]iodide method. In brief, 50 ml of a solution of 2 0 -deoxycytidine hydrochloride (2.63 mg in 1 ml 0.5 M acetate buffer pH 5; Sigma, Germany) were mixed with the Na 131 I-solution (Amersham, Germany) in a screw-cap-vial. A volume of 20 ml of a solution of Tl(TFA) 3 (5.43 mg in 1 ml 0.5 M acetate buffer pH 5.0) was added and the mixture was heated for 1 h to 601C. A measure of 20 ml of a sodium thiosulfate solution (10 mg in 1 ml 0.5 M acetate buffer pH 5.0) was added and the mixture separated by RP-HPLC. Elution with a linear gradient of a methanol/Trisphosphate buffer (pH 2.6) over 30 minutes yielded noncarrier added 5-[
131 I]iodo-deoxycytidine. Under these conditions, the product eluted after 12.5 minutes. The collected eluate was evaporated to dryness, redissolved in sterile 0.9% NaCl solution and neutralized. The average radiochemical yield was 72%. MeWo wild-type cells on the right flank. Therefore, the cells were suspended in 100 ml OPTI-MEM I medium. The in vitro duplication times for MeWo K4 cells and MeWo wild-type cells were approximately 24 hours. After the animals had developed palpable nodules of 10 mm in diameter, 350 mCi 131 I-deoxycytidine was injected into the lateral tail vein. The uptake of iodide in the thyroid gland was blocked by i.p. injection of 0.5 ml of 0.9% NaI-solution 24 hours before. At 24 and 48 hours postinjection, four animals were killed and dissected. The organs were weighed and counted in a gamma counter (Cobra II Auto-Gamma, Canberra Packard) with the counting window set from 260 to 470 keV.
Statistical analysis
Statistical procedures were performed with SigmaPlot 8.0. (SPSS GmbH Software, Munich, Germany). Statistical significance was determined by the t-test. A Po.05 value was chosen for statistical significance.
Results rAAV particles carrying the enhancer/hMIA promoter mediate tissue-specific reporter gene expression In order to determine transduction efficiency as well as transcriptional activity and specificity of the recombinant viral particles three different melanoma cell lines (B16, MeWo, SK-Mel-23) and one cervix carcinoma cell line (HeLa) were infected with either rAAV/CMV-EGFP or rAAV/hMIAIV-EGFP. Cells were incubated at an MOI of 20 with the viral particles. At 2 days after infection, expression of the EGFP gene was evaluated by flow cytometry (Fig 2) . rAAV/CMV-EGFP infection resulted in a significant EGFP expression in all cell lines, with green fluorescence being detected in about 74% of HeLa cells, 54% of B16 cells, 62% of MeWo cells and 82% of SK-Mel-23 cells. In contrast, infection with rAAV/ hMIAIV-EGFP resulted in EGFP expression exclusively in melanoma cells, with significant green fluorescence being detected in about 26% of B16 cells, 56% of MeWo cells and 50% of SK-Mel-23 cells. In HeLa cells, no significant green fluorescence was observed, demonstrating the tissue-specific activity of the enhancer/hMIA promoter construct.
In general, the number of transduced cells as well as the level of reporter gene expression within the transduced cells was significantly higher when infection was performed with rAAV/CMV-EGFP particles. This indicates the stronger but unspecific transcriptional activity of
Selective uptake of GCV after infection with the HSVtkbearing viral particles
Since the EGFP expression analysis demonstrated tissuespecific activity of the enhancer/hMIA promoter construct, recombinant viral particles were employed to mediate HSVtk gene expression. In order to estimate HSVtk activity, uptake experiments with the specific HSVtk substrate GCV were performed because it has been shown that GCV uptake positively correlates with the activity of HSVtk. 37 Therefore, the melanoma and the cervix carcinoma cell lines were infected with rAAV/ hMIAIV-HSVtk, rAAV/hMIA(493)IV-HSVtk or rAAV/ CMV-HSVtk and incubated with 3 H-GCV (Fig 3) . Compared to noninfected cells, transduction with the CMV promoter construct induced in HeLa cells a 20-fold, in MeWo cells a 32-fold, in B16 cells a four-fold and in SK-Mel-23 cells a 31-fold increase in GCV uptake. Whereas infection with rAAV/hMIAIV-HSVtk and rAAV/hMIA(493)IV-HSVtk mediated in MeWo cells a 20-fold and 11-fold, in B16 cells a five-fold and two-fold and in SK-Mel-23 cells a 13-fold and seven-fold higher GCV uptake, respectively. HeLa cells infected with either of the enhancer/hMIA promoter constructs exhibited no significant change in GCV uptake. These results clearly indicated that both hMIA-based expression systems conferred tissue-specific HSVtk activity with rAAV/ hMIAIV-HSVtk being slightly more efficient. Since the FACS data showed no difference in transduction efficiency between B16 and other cell lines, the low uptake of GCV in B16 cells is rather due to a low transport of GCV by B16 cells.
Growth inhibition and thymidine uptake after treatment with GCV
To assess the efficiency of the HSVtk/GCV suicide system, cytotoxic effects after infection of the melanoma and cervix carcinoma cell lines with the recombinant viral particles followed by GCV treatment were evaluated. At 2 days after GCV treatment, growth inhibition was measured by counting the number of viable cells. In comparison to untreated cells infection with rAAV/CMVHSVtk resulted in a statistically significant growth inhibition of 72% for HeLa cells, 76% for MeWo cells, 78% for B16 cells and 68% for SK-Mel-23 cells. In contrast, infection with rAAV/hMIAIV-HSVtk and rAAV/hMIA(493)IV-HSVtk particles caused statistically significant growth inhibition only in melanoma cells: 60 and 68% for MeWo cells, 60 and 47% for B16 cells, 61 and 53% for SK-Mel-23 cells, respectively, whereas for HeLa cells no significant growth inhibition was observed (data not shown).
Inhibition of cell proliferation due to the metabolization of GCV was also determined by performing 3 Hthymidine uptake experiments. Thymidine as a specific nucleoside of DNA synthesis represents a proliferation marker whose incorporation into the DNA is reduced in consequence of a cytotoxic effect. Therefore, 2 hours after initiation of GCV treatment the infected and noninfected cells were incubated with 3 H-labeled thymidine for 4 hours and radioactivity incorporated into the DNA was counted (Fig 4) . In comparison to untreated cells, transduction with the CMV promoter based construct mediated a statistically significant decrease in thymidine incorporation of 60% for HeLa cells, 89% for MeWo cells, 58% for B16 cells and 80% for SK-Mel-23 cells, whereas infection with the rAAV/hMIAIV-HSVtk and Exposure of noninfected cells to GCV had no significant effect on cell growth or thymidine uptake in any cell line. Similarly, rAAV infection without GCV treatment had no significant effect on these parameters in three of the four cell lines. Only in SK-Mel 23 cells, rAAV infection without GCV application induced a growth inhibition of approximately 41% and a decreased thymidine uptake of about 36% in comparison to untreated cells.
Thus, these results demonstrated that a strong cytotoxic effect is induced in all cell line after infection with the CMV construct and GCV treatment, while infection with the enhancer/MIA promoter-based constructs and GCV treatment caused a cytotoxic effect only in the melanoma cell lines, indicating a tissue-specific activity of the HSVtk/GCV system in vitro. Interestingly, depending on the cell line tested, the enhancer/hMIA promoterbased constructs were nearly as efficient in mediating growth inhibition and thymidine uptake as the CMV promoter-based system.
Evaluation of in vivo growth of transiently transduced tumor cells
In a subsequent experiment, the influence of transient rAAV/hMIAIV-HSVtk transduction on in vivo growth of MeWo cells was evaluated in nude mice. We selected this cell line, since MeWo cells showed the strongest effect in all experiments and were not affected by AAV infection alone. Therefore, noninfected MeWo cells and cells infected overnight with rAAV/hMIAIV-HSVtk were injected s.c. in the right flank of nude mice. After 2-3 weeks, when the tumors grew to 0.5 cm in diameter, GCV treatment was initiated with an i.p. injection daily. Unfortunately, noninfected tumor cells as well as rAAV/hMIAIV-HSVtk infected tumor cells still grew during continuous GCV application. A significant difference in tumor growth between noninfected cells and infected cells could not be observed (data not shown). Therefore, the experiment was terminated after 27 days.
In a succeeding experiment, transiently transduced HeLa cells were employed. Noninfected HeLa cells and cells infected overnight with rAAV/CMV-HSVtk and rAAV/hMIAIV-HSVtk, respectively, were injected s.c. in the right flank of nude mice. Again GCV treatment was initiated with an i.p. injection daily when the tumors grew to 0.5 cm in diameter. During continuous GCV administration of 30 days, a constant tumor growth was seen without significant difference between non-infected HeLa cells and cells infected with rAAV/CMV-HSVtk or rAAV/hMIAIV-HSVtk (data not shown). Thus, after rAAV-mediated transduction and GCV treatment, no antitumor effect in comparison to noninfected cells could be observed. Even for HeLa cells expressing HSVtk under the control of the strong viral CMV promoter, no cytotoxic effect was detectable, leading to the assumption that nontransduced tumor cells were selected by GCV treatment and grew out as a tumor.
Influence of stable HSVtk-expression on in vivo tumor growth
It was postulated that in contrast to transient HSVtk expression, stable HSVtk transduction might have a significant effect on the development of tumor growth. Therefore, a stable HSVtk-expressing MeWo cell line was generated. MeWo cells were infected with rAAV particles carrying the HSVtk and the EGFP gene, under the control of the hMIA(493)IV elements. Owing to the limited packing capacity of AAV particles, the minimal promoter fragment was used to drive gene expression although the preceding experiments demonstrated that its activity was slightly reduced compared to the 1386 bp promoter. MeWo cells were infected with rAAV/ hMIA(493)IV-HSVtk-IRES2-EGFP and sorted through flow cytometry for EGFP-positive single cells. Thereafter, six clones were screened by flow cytometry for up to 100% EGFP-positive cells (data not shown). The clone with the highest HSVtk activity (MeWo K4) was then chosen and used in further experiments.
In MeWo K4 cells, a strong increase in GCV uptake (234-fold higher) in comparison to wild-type cells was found in vitro (data not shown). After a 3 day treatment with GCV, a growth inhibition of 87% could be measured for MeWo K4 cells but not for MeWo wild-type cells, also thymidine uptake experiments revealed a decrease of 93% in thymidine incorporation for MeWo K4 cells treated with GCV, but not for untreated or wild-type cells (data not shown). Thus, in vitro a strong HSVtk activity in MeWo K4 cells with high sensitivity towards GCV was confirmed.
To evaluate HSVtk expression in vivo, uptake of the HSVtk substrate 131 I-deoxycytidine in MeWo K4 tumors was examined. Therefore, nude mice with MeWo K4 tumors on the left flank and MeWo wild-type tumors on the right flank were killed and dissected 24 and 48 hours after i.v. application of 131 I-deoxycytidine and uptake of the tracer was measured in organs and tumors (Fig 5) . After 24 hours, a statistically significant 2.4-fold higher incorporation of 131 I-deoxycytidine in MeWo K4 tumors (951809 CPM/g) in comparison to MeWo wild-type tumors (398439 CPM/g) was seen, while after 48 hours, a statistically significant 3.3-fold higher incorporation of 131 I-deoxycytidine in MeWo K4 tumors (717627 CPM/g) in comparison to MeWo wild-type tumors (220782 CPM/g) was measured. The uptake in other organs was lower with the highest accumulation in the spleen (732461 CPM/g after 24 hours, 406695 CPM/g after 48 hours). Consequently, with regard to the in vitro results, this may be an evidence for an HSVtk activity of MeWo K4 cells in vivo.
Finally, the influence of stable HSVtk expression and GCV treatment on the development of MeWo K4 cells in nude mice was evaluated. Therefore, MeWo wild-type cells and MeWo K4 cells were injected s.c. in the right flank of nude mice. When the tumors grew to 0.5 cm in diameter, GCV treatment was initiated again with two i.p.
Tissue-specific gene therapy of malignant melanoma F Schoensiegel et al injections daily. While the relative tumor growth rate increased in mice with MeWo wild-type tumors, the relative tumor growth rate decreased in mice with stable MeWo K4 tumors (Fig 6) , whereas a statistically significant difference in the relative tumor growth rate could be observed from the seventh day of GCV treatment. After 27 days of continuous GCV treatment all mice with MeWo K4 tumors were tumor free. Furthermore, at 22 weeks after the end of treatment the animals were still tumor free. Thus, using a stable HSVtk-expressing cell line eradication of malignant melanoma was seen demonstrating stable promoter activity in vivo as well as therapeutic efficiency of the suicide system.
Discussion
Tissue-specific promoters have been used in a variety of tumors to direct expression of therapeutic genes. Examples include the alpha-fetoprotein promoter that has been used to target gene expression to hepatocellular carcinomas, 38 the c-erb B2 promoter to target expression to breast and pancreatic carcinomas, 39 the surfactant protein promoter to target lung cancer cells, 40 and the calcitonin promoter-enhancer to target medullary carcinoma. 41 In addition, there are examples of tissue-specific gene expression in prostate cancer, 42 glioma cells 43 and osteosarcoma. 44 In this study, the use of the human melanoma inhibitory activity promoter (hMIA) for suicide gene therapy of malignant melanoma was evaluated. MIA has been characterized as a protein secreted by all primary and metastatic malignant melanoma and in addition by chondrosarcomas and many adenocarcinomas, including colorectal and breast cancer. 28, 31, 32 The MIA gene was independently cloned by differential display comparing differentiated and dedifferentiated chondrocytes and has been named cartilage-derived retinoic acid-sensitive protein (CD-RAP). 45 While MIA mediates the detachment of melanoma cells from extracellular matrix molecules such as fibronectin, 26 its expression in non-neoplastic tissues is only activated during the initiation of chondrogenesis throughout cartilage development indicating a highly selective expression pattern of the MIA gene. 31, 45 Two different variants, a full-length 1386 bp and a minimal 493 bp MIA promoter fragment were employed to drive selective gene expression. Since both fragments alone exhibited only weak transcriptional activity (data not shown), they were fused to four tandem copies of the enhancer of the murine tyrosinase gene. Previous in vitro studies on the transcriptional activity of enhancer/hMIA combinations demonstrated that four copies were superior in increasing gene expression when combinations with 1-5 enhancers were analyzed. 34 Both enhancer/hMIA promoter combinations were packed into rAAV particles. A succeeding reporter gene expression analysis demonstrated that the corresponding particles efficiently infected tumor cells and were superior to naked plasmid transfection of the cells, 34 although rAAV particles containing the CMV promoter exhibited higher transduction efficiency and stronger transcriptional activity. But most importantly, the enhancer/hMIA promoter constructs in contrast to the CMV promoter restricted gene expression to melanoma cell lines, no reporter gene expression was Tissue-specific gene therapy of malignant melanoma F Schoensiegel et al detectable in the cervix carcinoma cell line. This pattern of tissue-specific activity was also observed when the enhancer/hMIA promoter containing rAAV particles were used to drive HSVtk expression. Enhanced uptake of the HSVtk substrate GCV, growth inhibition and decreased 3 H-thymidine incorporation into the DNA after GCV treatment could only be observed for tumor cells of the melanocytic origin. Interestingly, infection with rAAV particles carrying either of the enhancer/ hMIA promoter combinations mediated nearly as efficient cytotoxic effects as the CMV promoter-based constructs. This might be explained by the highly toxic activity of only a few GCV-triphosphate molecules per cell as well as by the bystander effect that also causes death of neighboring nontransduced cells.
In previous studies on suicide gene therapy of melanoma, the murine tyrosinase promoter has been used for tissuespecific expression of HSVtk. 20, 21, 24, 25 This promoter is almost exclusively active in melanocytes and in most but not all human melanomas. 46 In contrast, hMIA promoter activity correlates with melanoma progression. 28, 47 Therefore, the MIA promoter may confer melanoma-restricted expression of the suicide gene also in advanced stages of the disease. The successful use of enhancer elements to increase transcriptional activity of weak tissue-specific promoters has been demonstrated in previous studies: a hypoxia-inducible enhancer linked to the human alphafetoprotein promoter has been shown to enhance selective suicide gene expression in hepatocellular carcinoma. 48 In another study, heterologous hypoxic and cytokineinducible enhancers have been used to increase endothelial cell-specific expression. 49 In vivo experiments in nude mice demonstrated that tumors originating from human melanoma cells transiently transduced with the HSVtk gene under control of the enhancer/hMIA promoter were not affected in their outgrowth during 27 days of continuous GCV treatment. A similar result was obtained when mice were challenged with transiently transduced HeLa cells expressing HSVtk under control of the strong viral CMV promoter. This may be due to the fact that a certain number of nontransduced tumor cells grew out as a tumor. This assumption is supported by the observation that tumors stable expressing the HSVtk gene under control of the enhancer/hMIA promoter responded to GCV application. Such tumors exhibited an increased accumulation of the HSVtk specific substrate 131 I-deoxycytidine and totally disappeared after 27 days of continuous GCV application. Even 22 weeks after the end of the treatment, no tumor recurrence was detectable. Although some studies showed that at the doses needed to eliminate the tumor, GCV causes leukopenia, diarrhea, 508 and some treatment-related mortality, 51 in our experiments GCV treatment did not cause such symptoms in the animals. Also, we did not observe weight loss during GCV therapy.
A systemic administration of rAAV for gene therapy in vivo was not performed, because the ex vivo infection of tumor cells followed by transplantation of the cells into the animals did not result in a satisfying infection efficiency. Therefore, after failure of the ex vivo gene transfer the approach using a stable HSVtk expressing melanoma cell line was chosen to demonstrate the in vivo efficiency of the HSVtk/GCV system under control of the MIA promoter for therapy of malignant melanoma. Since other studies showed that HSVtk expression controlled by unspecific promoters lead to disappearance of the tumor, 52 a similar experiment with stable CMV-HSVtktransduced melanoma cells was not performed. In the future, the in vivo transduction efficiency has to be improved, in order to achieve a therapeutically sufficient enzyme activity after a single or a repeated application of virus particles.
Recently, the first results of a phase I/II clinical study with retroviral particles bearing the HSVtk gene for suicide therapy of melanoma were reported. 53 Vector-producing cells were injected directly into metastatic nodules of the patients, and GCV administration followed 7 days later. However, the tumor response was limited. The injected nodules were slightly reduced in size, noninjected nodules continued to grew and the disease progressed. It can be speculated that suicide gene therapy becomes more effective when in parallel the immune system of the patient is triggered. Through the induction of cell death, high amounts of tumor antigens are released, which can be picked up by professional antigen-presenting cells. These cells, when activated by specific immunotherapeutic signals, might have the capability to induce a strong T-cell-mediated immunity against the tumor.
In conclusion, rAAV particles carrying the human MIA promoter combined with four enhancers of the murine tyrosinase gene-mediated tissue-specific gene expression in vitro. In addition, the results of the in vivo experiments may also be an indicator for a stable transcriptional activity in vivo. Since AAV is not associated with any human disease and classified to be defective in replication, these particles exhibit advantages in comparison to other gene transfer systems. Thus, in face of higher transduction efficiency and easier generation, these viral constructs might be a promising tool in melanoma gene therapy and vectors bearing the hMIA promoter may be further evaluated in other forms of cancer where MIA is expressed.
